Your browser doesn't support javascript.
Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines.
Hwang, Jimin; Lee, Se Bee; Lee, Seung Won; Lee, Min Ho; Koyanagi, Ai; Jacob, Louis; Tizaoui, Kalthoum; Yon, Dong Keon; Shin, Jae Il; Smith, Lee.
  • Hwang J; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
  • Lee SB; Ulsan University College of Medicine, Seoul, Republic of Korea.
  • Lee SW; Department of Data Science, Sejong University College of Software Convergence, Seoul, South Korea.
  • Lee MH; Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Koyanagi A; Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain; ICREA, Pg. Lluis Companys 23, Barcelona, Spain.
  • Jacob L; Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny
  • Tizaoui K; Laboratory of Microoranismes and Active Biomolecules, Sciences Faculty of Tunis, Tunis El Manar University, Tunis, Tunisia.
  • Yon DK; Department of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: yonkkang@gmail.com.
  • Shin JI; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: shinji@yuhs.ac.
  • Smith L; The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK.
J Autoimmun ; 122: 102681, 2021 08.
Article in English | MEDLINE | ID: covidwho-1270603
ABSTRACT
Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thrombosis / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Autoimmun Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: J.jaut.2021.102681

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thrombosis / COVID-19 Vaccines / COVID-19 Type of study: Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Autoimmun Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: J.jaut.2021.102681